xCures has announced it is partnering with CancerCompass to allow consumers who contact CancerCompass to access the xCures’ platform and services. xCures’ comprehensive cancer case review service includes a high-quality Cancer Journey patient summary created by the xCures team that organizes and summarizes a patient’s medical records. These summaries are reviewed by xCures’ clinical scientists to identify appropriate treatment possibilities, which could include a highly curated set of novel therapies and multi-drug combinations vetted by leading oncologists and cancer scientists. xCures then provides patients with a summary report that they can share with their oncologists and health-care providers. The report includes a list of top options, the rationale supporting each recommendation and how to access the options. xCures even assists patients in accessing their preferred options. That assistance could include contacting clinical trial sites, obtaining investigational therapies through managed access and compassionate use programs, and petitioning for insurance coverage for off-label use of approved drugs. “xCures partnering with CancerCompass is a significant step toward improving access to personalized knowledge about advanced cancer treatment options,” said xCures CEO Mika Newton in the press release. “This is important progress in our mission to broaden the availability of our comprehensive cancer case review services, positively affecting the largest number of cancer patients and their physicians.”
To view the full press release, visit https://ibn.fm/hPh1Y
About xCures Inc.
xCures operates an AI-assisted platform that connects cancer patients and physicians with optimal investigational or approved therapies. The platform prospectively generates real-world evidence for clinical studies and decentralized trials. For more information about the company, please visit www.xCures.com.
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
InvestorWire is part of the InvestorBrandNetwork.